NeuroPace (NASDAQ:NPCE – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.
A number of other research analysts also recently issued reports on the company. Guggenheim reaffirmed a “neutral” rating on shares of NeuroPace in a report on Wednesday, July 29th. Mizuho decreased their target price on shares of NeuroPace from $22.00 to $12.00 and set an “outperform” rating on the stock in a research note on Monday, November 16th. Leerink Partners downgraded shares of NeuroPace from an “outperform” rating to a “market perform” rating and set a $7.00 price target on the stock. in a report on Friday, November 13th. Weiss Ratings lowered shares of NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. Finally, Wells Fargo & Company lowered shares of NeuroPace from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $19.00 to $9.00 in a research report on Friday, November 13th. Five equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $13.11.
Read Our Latest Stock Analysis on NPCE
NeuroPace Stock Performance
Insider Activity
In other news, CEO Joel Becker purchased 11,891 shares of the company’s stock in a transaction that occurred on Tuesday, November 17th. The stock was purchased at an average cost of $8.35 per share, for a total transaction of $99,289.85. Following the completion of the transaction, the chief executive officer owned 149,891 shares of the company’s stock, valued at $1,251,589.85. This trade represents a 8.62% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Patrick F. Williams purchased 11,891 shares of NeuroPace stock in a transaction dated Tuesday, November 17th. The shares were bought at an average price of $8.34 per share, for a total transaction of $99,170.94. Following the acquisition, the chief financial officer owned 79,399 shares in the company, valued at approximately $662,187.66. This trade represents a 17.61% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have bought 36,282 shares of company stock valued at $302,086. Company insiders own 19.20% of the company’s stock.
Hedge Funds Weigh In On NeuroPace
Institutional investors have recently bought and sold shares of the company. Legal & General Group Plc purchased a new stake in shares of NeuroPace in the 2nd quarter valued at approximately $41,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in NeuroPace in the second quarter valued at approximately $157,000. Entropy Technologies LP acquired a new position in NeuroPace in the third quarter valued at approximately $146,000. Diversified Trust Co purchased a new position in NeuroPace in the third quarter worth approximately $153,000. Finally, Bank of America Corp DE purchased a new position in NeuroPace in the second quarter worth approximately $322,000. 78.83% of the stock is owned by hedge funds and other institutional investors.
About NeuroPace
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
Recommended Stories
- Five stocks we like better than NeuroPace
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
